The past year for Ligia Pinto, Ph.D., and her staff has been full of pressure and remote meetings at all hours of the day and night. It’s also been one of partnerships and progress. Pinto heads the Vaccine, Immunity, and Cancer Directorate, the group at the Frederick National Laboratory that’s leading the national SARS-CoV-2 Serological Sciences Network (SeroNet). At this time last year, her laboratories, which specialized in human papillomavirus, antibody science, and serology, had just been asked to help the Food and Drug Administration evaluate the quality of the new SARS-CoV-2 antibody tests that were flooding the market.

Researchers have found a potential therapeutic target for lung squamous cell carcinoma (LSCC), the second most prevalent type of lung cancer. This may pave the way for a targeted therapy for LSCC, which currently has no approved targeted therapies.

Used successfully in several industries, digital twins have the potential to forge a path toward advances in cancer care and research. Frederick National Laboratory is a lead organization in the strategic interagency collaboration between the National Cancer Institute and the U.S. Department of Energy and has been instrumental in the development of innovative technologies for creating a cancer patient digital twin.

Researchers in the National Cancer Institute’s Center for Cancer Research (CCR) and the Frederick National Laboratory’s Basic Science Program have discovered molecules that could keep the body from working against a cancer treatment.

The Scientific Library recently hosted its first virtual discussion of 2021, featuring Yvonne A. Evrard, Ph.D., operations manager for the NCI Patient-Derived Models Repository at NCI at Frederick and the Frederick National Laboratory for Cancer Research. These virtual discussions are one way the Library uses its position as a research information hub to engage scientific researchers through collaboration, interaction, and discussion.